Vaxart Board Approves Reverse Split Proposal

An announcement from Vaxart ( (VXRT) ) is now available.

On May 16, 2025, Vaxart announced that its board of directors approved resolutions to narrow the proposed reverse split range and reduce authorized shares at future stockholder meetings. The company urged stockholders to vote in favor of the reverse stock split proposal at the upcoming annual meeting to avoid Nasdaq delisting. Leading proxy advisory firms ISS and Glass Lewis support the proposal, which aims to maintain Vaxart’s Nasdaq listing, preserving stockholder liquidity and enabling investment from institutional investors.

The most recent analyst rating on (VXRT) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Vaxart stock, see the VXRT Stock Forecast page.

Spark’s Take on VXRT Stock

According to Spark, TipRanks’ AI Analyst, VXRT is a Neutral.

Vaxart’s stock score reflects strong revenue growth and progress in clinical trials. However, significant profitability challenges, cash flow management issues, and bearish technical indicators weigh heavily on the stock. The risk of NASDAQ delisting and strategic initiatives such as the reverse stock split are key factors impacting the overall outlook. The company’s efforts to stabilize its financial position and improve operational efficiencies will be crucial for future stability.

To see Spark’s full report on VXRT stock, click here.

More about Vaxart

Vaxart is a clinical-stage biotechnology company focused on developing oral recombinant vaccines using its proprietary delivery platform. These vaccines are designed to be administered as pills, which can be stored and shipped without refrigeration, eliminating the risk of needle-stick injuries. Vaxart’s development programs include vaccines for coronavirus, norovirus, influenza, and a therapeutic vaccine for human papillomavirus (HPV). The company has filed broad patent applications for its technology and creations.

Average Trading Volume: 2,000,351

Technical Sentiment Signal: Sell

Current Market Cap: $91.29M

For an in-depth examination of VXRT stock, go to TipRanks’ Stock Analysis page.